Chlorogenic acid is reported to enhance the sensitivity of human hepatocellular carcinoma cells lines to regorafenib treatment by inhibiting PI3K/Akt/mTOR signaling [52] and lessening liver injury by inhibiting autophagy in a rat model of NAFLD [53]. The gene discussed is MTOR; the disease is metabolic dysfunction-associated steatotic liver disease.